Clinical impact of spacer placement surgery with expanded polytetrafluoroethylene sheet for particle therapy.
Expanded polytetrafluoroethylene
Particle therapy
Spacer placement surgery
Spacer-related complication
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
24 Oct 2023
24 Oct 2023
Historique:
received:
03
09
2023
accepted:
07
10
2023
medline:
26
10
2023
pubmed:
25
10
2023
entrez:
24
10
2023
Statut:
epublish
Résumé
Spacer placement surgery is useful in particle therapy (PT) for patients with abdominopelvic malignant tumors located adjacent to the gastrointestinal tract. This study aimed to assess the safety, efficacy, and long-term outcomes of spacer placement surgery using an expanded polytetrafluoroethylene (ePTFE) spacer. This study included 131 patients who underwent ePTFE spacer placement surgery and subsequent PT between September 2006 and June 2019. The overall survival (OS) and local control (LC) rates were calculated using Kaplan-Meier method. Spacer-related complications were classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0). The median follow-up period after spacer placement surgery was 36.8 months. The 3-year estimated OS and LC rates were 60.5% and 76.5%, respectively. A total of 130 patients (99.2%) were able to complete PT. Spacer-related complications of ≥ grade 3 were observed in four patients (3.1%) in the acute phase and 13 patients (9.9%) in the late phase. Ten patients (7.6%) required removal of the ePTFE spacer. Spacer placement surgery using an ePTFE spacer for abdominopelvic malignant tumors is technically feasible and acceptable for subsequent PT. However, severe spacer-related late complications were observed in some patients. Since long-term placement of a non-absorbable ePTFE spacer is associated with risks for morbidity and infection, careful long-term follow-up and prompt therapeutic intervention are essential when complications associated with the ePTFE spacer occur. retrospectively registered.
Sections du résumé
BACKGROUND
BACKGROUND
Spacer placement surgery is useful in particle therapy (PT) for patients with abdominopelvic malignant tumors located adjacent to the gastrointestinal tract. This study aimed to assess the safety, efficacy, and long-term outcomes of spacer placement surgery using an expanded polytetrafluoroethylene (ePTFE) spacer.
METHODS
METHODS
This study included 131 patients who underwent ePTFE spacer placement surgery and subsequent PT between September 2006 and June 2019. The overall survival (OS) and local control (LC) rates were calculated using Kaplan-Meier method. Spacer-related complications were classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).
RESULTS
RESULTS
The median follow-up period after spacer placement surgery was 36.8 months. The 3-year estimated OS and LC rates were 60.5% and 76.5%, respectively. A total of 130 patients (99.2%) were able to complete PT. Spacer-related complications of ≥ grade 3 were observed in four patients (3.1%) in the acute phase and 13 patients (9.9%) in the late phase. Ten patients (7.6%) required removal of the ePTFE spacer.
CONCLUSIONS
CONCLUSIONS
Spacer placement surgery using an ePTFE spacer for abdominopelvic malignant tumors is technically feasible and acceptable for subsequent PT. However, severe spacer-related late complications were observed in some patients. Since long-term placement of a non-absorbable ePTFE spacer is associated with risks for morbidity and infection, careful long-term follow-up and prompt therapeutic intervention are essential when complications associated with the ePTFE spacer occur.
TRIAL REGISTRATION
BACKGROUND
retrospectively registered.
Identifiants
pubmed: 37875956
doi: 10.1186/s13014-023-02359-5
pii: 10.1186/s13014-023-02359-5
pmc: PMC10594906
doi:
Substances chimiques
Polytetrafluoroethylene
9002-84-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
173Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Br J Surg. 2011 Apr;98(4):558-64
pubmed: 21246516
Cancer Med. 2017 Oct;6(10):2234-2243
pubmed: 28879658
Radiat Oncol. 2015 Feb 27;10:56
pubmed: 25886457
Adv Radiat Oncol. 2019 May 15;4(4):729-737
pubmed: 31673666
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):367-374
pubmed: 28463156
Radiat Oncol. 2021 Jan 6;16(1):3
pubmed: 33407648
Clin Oncol (R Coll Radiol). 2023 May;35(5):283-291
pubmed: 36804292
Cancer. 2010 May 15;116(10):2476-85
pubmed: 20225229
Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):928-38
pubmed: 12377347
World J Surg Oncol. 2016 Aug 09;14(1):211
pubmed: 27507254
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1097-103
pubmed: 10863083
J Clin Oncol. 2007 Mar 10;25(8):965-70
pubmed: 17350945
In Vivo. 2022 Sep-Oct;36(5):2473-2480
pubmed: 36099090
Am J Surg. 1999 Jul;178(1):22-5; discussion 25-6
pubmed: 10456697
J Appl Clin Med Phys. 2017 Jan;18(1):32-39
pubmed: 28291917
Radiother Oncol. 2020 May;146:194-199
pubmed: 32220700
Br J Radiol. 2021 Jan 01;94(1117):20200848
pubmed: 33095659
World J Surg Oncol. 2012 Feb 06;10:30
pubmed: 22309780
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):972-979
pubmed: 29485077
Dig Surg. 2022;39(2-3):99-108
pubmed: 35462363
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1177-85
pubmed: 25539373
J Gastroenterol. 2011 Jul;46(7):913-20
pubmed: 21516295
J Am Coll Surg. 2020 Feb;230(2):207-215
pubmed: 31765694
J Clin Oncol. 2007 Mar 10;25(8):953-64
pubmed: 17350944
J Radiat Res. 2021 May 12;62(3):549-555
pubmed: 33783533
Cancer. 2011 Nov 1;117(21):4890-904
pubmed: 21495022
J Surg Oncol. 2010 Jan 1;101(1):97-9
pubmed: 19798696
Asia Pac J Clin Oncol. 2022 Oct;18(5):e442-e447
pubmed: 35098680
Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):407-21
pubmed: 12023146
Clin Oncol (R Coll Radiol). 2023 May;35(5):292-300
pubmed: 36813694
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1084-91
pubmed: 16979840
J Surg Oncol. 2019 Aug;120(2):214-222
pubmed: 31075183
Radiat Oncol. 2020 Jul 22;15(1):178
pubmed: 32698843
Radiother Oncol. 1999 Feb;50(2):135-42
pubmed: 10368035
World J Gastroenterol. 2010 Apr 14;16(14):1800-3
pubmed: 20380016
Arch Surg. 2000 Oct;135(10):1212-7
pubmed: 11030884
Pract Radiat Oncol. 2013 Jul-Sep;3(3):199-208
pubmed: 24674365